Endpoint Health and Grifols have entered into a global licensing and collaboration agreement to develop and commercialisean Antithrombin III therapy for the treatment of sepsis. Grifols will pay up to US$25 M to support the drugs clinical development programme while Endpoint Health will be responsible for clinical development, regulatory submissions and commercialisation in the disease state. In return, Grifols will receive royalty payments from Endpoint Health in line with the nature of the project and based on the product’s future net sales.